TheraRadar
← Back
Data updated: Jun 28, 2026

CHEMI SPA

Generics

CHEMI SPA is a generic drug manufacturer focused on Oncology, Neurology.

2014
Since
4
Drugs
-
Trials
0
New Drugs (2yr)

CHEMI SPA's Key Drugs

CHEMI SPA's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

CHEMI SPA's Recent FDA Approvals

New NDA/BLA approvals for CHEMI SPA over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

CHEMI SPA's Therapeutic Areas

CHEMI SPA's approved drugs and pipeline span 2 therapeutic areas, led by Oncology and Neurology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 50%
1 drugs
Neurology 50%
1 drugs

CHEMI SPA's Top Competitors

CHEMI SPA's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

CHEMI SPA Pipeline Snapshot

Active clinical trials for CHEMI SPA across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Oncology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling